Rani director granted options on 123,600 shares

Rani Therapeutics Holdings director Lisa Ann Rometty received a stock option grant covering 123,600 shares of Class A common stock.

Rhea-AI Filing Summary

Rani Therapeutics Holdings director Lisa Ann Rometty received a stock option grant covering 123,600 shares of Class A common stock. The option has an exercise price of $0.9515 per share and expires on May 27, 2036.

The option vests in full on the first anniversary of the May 28, 2026 grant date, subject to her Continuous Service under the company’s 2021 Equity Incentive Plan. Vesting may occur earlier if either the company’s next annual stockholder meeting or a Change in Control occurs while she continues in service. Following this grant, she holds 123,600 option shares directly.

Insider Trade Summary

Grant/Award: 123,600 shares

Grant/Award 1 txn

Insider Rometty Lisa Ann

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	123,600	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 123,600 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.

Key Figures

Option grant size: 123,600 shares Exercise price: $0.9515 per share Underlying shares: 123,600 shares +2 more

5 metrics

Option grant size 123,600 shares Director stock option covering Class A common stock

Exercise price $0.9515 per share Conversion or exercise price of granted options

Underlying shares 123,600 shares Class A common stock underlying the option

Post-grant derivative holdings 123,600 shares Total option shares following the transaction

Option expiration May 27, 2036 Expiration date of director stock option

Key Terms

Director Stock Option (Right to Buy), 2021 Equity Incentive Plan, Continuous Service, Change in Control

4 terms

Director Stock Option (Right to Buy) financial

"security_title: "Director Stock Option (Right to Buy)""

2021 Equity Incentive Plan financial

"defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")"

Continuous Service financial

"subject to the Reporting Person's Continuous Service through such vesting date"

Change in Control financial

"upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rani Therapeutics (RANI) report for Lisa Ann Rometty?

Rani Therapeutics reported that director Lisa Ann Rometty received a stock option grant for 123,600 shares. The options relate to Class A common stock and are a compensation award, not an open-market purchase or sale, with vesting tied to continued board service.

How many RANI shares are covered by Lisa Ann Rometty’s new stock option grant?

The new stock option grant to Lisa Ann Rometty covers 123,600 underlying shares of Class A common stock. These shares become exercisable only after the vesting conditions are met and represent her post-grant derivative position reported in this Form 4 filing.

What is the exercise price and expiration date of Lisa Ann Rometty’s RANI options?

The option granted to Lisa Ann Rometty has an exercise price of $0.9515 per share and expires on May 27, 2036. She can exercise the options only after they vest, subject to the terms of the 2021 Equity Incentive Plan.

When do Lisa Ann Rometty’s Rani Therapeutics options vest?

The options vest in full on the first anniversary of the May 28, 2026 grant date, assuming Continuous Service. Vesting can also occur earlier upon the next annual stockholder meeting or a Change in Control, provided she remains in Continuous Service through that date.

Is Lisa Ann Rometty’s RANI Form 4 transaction a stock purchase or sale?

The Form 4 shows a grant of stock options, not an open-market purchase or sale. The transaction code is “A,” indicating a grant or award acquisition of derivative securities as compensation rather than a discretionary trade in Rani Therapeutics shares.

What is Lisa Ann Rometty’s RANI derivative holdings after this Form 4 grant?

After the reported grant, Lisa Ann Rometty holds 123,600 options linked to Class A common stock directly. This reflects her derivative position following the grant, with no additional remaining derivative positions disclosed in the derivative summary of this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rometty Lisa Ann

(Last) (First) (Middle)

C/O RANI THERAPEUTICS LLC

2051 RINGWOOD AVE

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$0.9515	05/28/2026		A		123,600		(1)	05/27/2036	Class A Common Stock	123,600	$0	123,600	D

Explanation of Responses:

1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.

	/s/ Svai Sanford, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)